SMP-3124LP in Adults With Advanced Solid Tumors
An Open-label, Phase I Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Preliminary Antitumor Activity of SMP 3124LP in Adults with Advanced Solid Tumors
Solid Tumor
DRUG: SMP3124LP
Determination of the Recommended Phase 2 Dose by Assessing Dose-limiting Toxicities (DLTs), 28 days|Number of Participants With Adverse Events and Serious Adverse Events, 6 months|Determine the Objective Response Rate (ORR), 6 months
The maximum concentration (Cmax) of SMP-3124 and SMP-3124LP, 6 months|The area under the curve (AUC) of SMP-3124 and SMP-3124LP, 6 months|The duration of response (DOR) assessed Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, 6 months
Phase 1/2, global, multicenter, open-label, first-in-human, clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of SMP-3124